Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Grows By 35.4%

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 122,300 shares, a growth of 35.4% from the December 15th total of 90,300 shares. Based on an average daily trading volume, of 169,400 shares, the short-interest ratio is presently 0.7 days. Approximately 0.3% of the company’s shares are sold short.

Institutional Trading of Achilles Therapeutics

A hedge fund recently raised its stake in Achilles Therapeutics stock. XTX Topco Ltd grew its holdings in Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 51,660 shares of the company’s stock after buying an additional 36,441 shares during the quarter. XTX Topco Ltd owned approximately 0.13% of Achilles Therapeutics worth $42,000 at the end of the most recent quarter. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Trading Down 0.9 %

ACHL stock opened at $1.16 on Thursday. The stock has a market capitalization of $47.68 million, a price-to-earnings ratio of -0.70 and a beta of 1.32. The firm’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $0.93. Achilles Therapeutics has a 12-month low of $0.63 and a 12-month high of $1.76.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.